TME Pharma Extends Debt Maturity to June 2028, Adds Bonds
TME Pharma extended all outstanding debt maturity to June 30, 2028, repaid approximately €0.76 million early, and added a €250,000 CEO bond and a €500,000 Hexagon bond. The Hexagon bond carries 10% interest and 2 million warrants.